A Phase 2 study of TAS-115 in patients with IPF

A PHASE 2, OPEN LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TAS-115 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223842

Enrollment

Registered

2018-03-15

Start date

2018-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis

Interventions

investigational material(s) Generic name etc : TAS-115 INN of investigational material : - Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Provided written informed consent 2. Confirmed IPF within five years of the registration 3. Have more than 50% of Forced vital capacity 4. Satisfies any of the following Have a history of treatment either with Pirfenidone or Nintedanib Have a history of treatment neither with Pirfenidone nor Nintedanib 5. Able to take medications orally etc.

Exclusion criteria

Exclusion criteria: 1. Airways obstruction 2. A serious illness or medical condition etc.

Design outcomes

Primary

Measure	Time frame
efficacy Forced vital capacity Pulmonary function tests	—

Secondary

Measure	Time frame
safety efficacy Safety, Efficacy Pulmonary function tests, Adverse event	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026